• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schering acquires Japanese rights to MS-325

Article

An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral

An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral vascular disease with MRI.

Schering gained worldwide sales and marketing rights to the product, excluding Japan, in June. The terms of the latest deal call for Schering to pay Epix $3 million up front, along with additional milestone payments. Simultaneously with this transaction, Epix reacquired rights to the Japanese market for MS-325 from Daiichi Radioisotope Laboratories. Under terms of that agreement, Epix will pay Daiichi $2.8 million in up-front fees and additional milestone payments. Daiichi will also receive a royalty from Epix on net sales of MS-325 in Japan.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.